A new blood test that uses artificial intelligence (AI) may offer a faster, more accurate way to determine whether pancreatic cancer treatment is working. Known as ARTEMIS-DELFI, the test detects DNA fragments shed by pancreatic tumors that circulate in blood.

In two large clinical trials of immunotherapy for metastatic pancreatic cancer, researchers successfully applied the test to identify patients with therapeutic responses. Two months after starting treatment, ARTEMIS-DELFI was better at predicting outcomes than imaging or other existing clinical and molecular markers.

“Early determination of response to therapy is crucial for patients with pancreatic or other cancers, especially when treated with immunotherapy where we do not have good biomarkers of response,” senior author Victor V

See Full Page